All Stories

IconOVir, 4 years on from flashy launch, sells oncolytic virus to UroGen for $4M in stock

IconOVir, 4 years on from flashy launch, sells oncolyti...

Feb 20, 2025 0

UroGen Pharma has opened another front in its attack on bladder cancer, paying I...

Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Incyte pens $885M biobucks AI pact to use Genesis' GEMS...

Feb 20, 2025 0

Incyte is sticking to its strategy this year of finding “early-stage, exotic stu...

It's curtain closed for Spotlight: Gene editing biotech shutters

It's curtain closed for Spotlight: Gene editing biotech...

Feb 20, 2025 0

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendsch...

Flourish Research makes deal with Diablo to acquire the California-based clinical research facility

Flourish Research makes deal with Diablo to acquire the...

Feb 20, 2025 0

Clinical trial organization Flourish Research has made a deal with Diablo Clinic...

Fierce Biotech Layoff Tracker 2025: Moderna lays off 50 employees; Spotlight winds down

Fierce Biotech Layoff Tracker 2025: Moderna lays off 50...

Feb 19, 2025 0

As always, if you know of layoffs occurring at a biotech, please reach out to th...

It's curtain close for Spotlight: Gene editing biotech shutters

It's curtain close for Spotlight: Gene editing biotech ...

Feb 19, 2025 0

CRISPR-based Spotlight Therapeutics has shut down, former CEO Mary Haak-Frendsch...

Cabaletta's CAR-T shows 'robust benefit' in lupus patients, teeing up registrational trial plans

Cabaletta's CAR-T shows 'robust benefit' in lupus patie...

Feb 19, 2025 0

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows...

UPDATE: RFK Jr. says HHS is 'bringing back common sense' with new messaging on 'biological truth'

UPDATE: RFK Jr. says HHS is 'bringing back common sense...

Feb 19, 2025 0

While the FDA’s diversity guidance for clinical trials has been temporarily rest...

Charles River lays off staffers at Memphis cell therapy manufacturing site

Charles River lays off staffers at Memphis cell therapy...

Feb 19, 2025 0

Charles River Laboratories is continuing to downsize certain parts of its organi...

Deep Track nominates candidates for Dynavax's board, launching proxy fight to end company's 'empire-building' strategy

Deep Track nominates candidates for Dynavax's board, la...

Feb 19, 2025 0

After privately vying for a change to Dynavax’s corporate strategy for months, l...

UPDATE: HHS is 'bringing back common sense' with new messaging on 'biological truth'

UPDATE: HHS is 'bringing back common sense' with new me...

Feb 19, 2025 0

While the FDA’s diversity guidance for clinical trials has been temporarily rest...

Siemens Healthineers plans 'mega depots' to bolster US supply chain amid 'geopolitical uncertainties'

Siemens Healthineers plans 'mega depots' to bolster US ...

Feb 19, 2025 0

Siemens Healthineers aims to speed up deliveries to customers with new “mega dep...

Deep Track nominates candidates for Dynavax's board, launching proxy fight to end company’s 'empire-building' strategy

Deep Track nominates candidates for Dynavax's board, la...

Feb 19, 2025 0

After privately vying for a change to Dynavax’s corporate strategy for months, l...

Altitude Lab sources funding, lab space for biotechs concerned about fate of NIH grants

Altitude Lab sources funding, lab space for biotechs co...

Feb 19, 2025 0

Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs c...

Cabaletta’s CAR-T shows ‘robust benefit’ in lupus patients, teeing up registrational trial plans

Cabaletta’s CAR-T shows ‘robust benefit’ in lupus patie...

Feb 19, 2025 0

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows...

Siemens Healthineers plans ‘mega depots’ to bolster US supply chain amid ‘geopolitical uncertainties’

Siemens Healthineers plans ‘mega depots’ to bolster US ...

Feb 19, 2025 0

Siemens Healthineers aims to speed up deliveries to customers with new “mega dep...

Ascletis' swift surge into obesity continues with competitive oral GLP-1 data

Ascletis' swift surge into obesity continues with compe...

Feb 19, 2025 0

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed ...

Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial

Australian biotech points to potential superbug use as ...

Feb 19, 2025 0

Recce Pharmaceuticals’ synthetic anti-infective gel successfully treated a range...

Remote blood sample collector maker YourBio Health revamps leadership team

Remote blood sample collector maker YourBio Health reva...

Feb 19, 2025 0

The Flagship Pioneering portfolio company appointed Paul Owen as its CEO last ye...

Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner

Radiance rolls into ROR1 race, paying $15M for ADC riva...

Feb 19, 2025 0

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China...

Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens

Merck pens $300M-per-product collab with Epitopea to lo...

Feb 19, 2025 0

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biot...

Options shrink for Supernus depression drug candidate after key trial failure

Options shrink for Supernus depression drug candidate a...

Feb 19, 2025 0

Supernus Pharmaceuticals may have had a potential path forward for its depressio...

FDA's clinical trial diversity guidance carries new message from Trump administration

FDA's clinical trial diversity guidance carries new mes...

Feb 19, 2025 0

While the FDA’s diversity guidance for clinical trials has been temporarily rest...

FDA’s clinical trial diversity guidance carries new message from Trump administration

FDA’s clinical trial diversity guidance carries new mes...

Feb 19, 2025 0

While the FDA’s diversity guidance for clinical trials has been temporarily rest...

2
3
4
5
6

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.